Technology ID
TAB-3599
Repurposing CDK Inhibitors for the Treatment of Zika Virus Infection
E-Numbers
E-202-2016-0
Lead Inventor
Zheng, Wei (NCATS)
Co-Inventors
Huang, Ruili (NCATS)
Xu, Miao (NCATS)
Huang, Wenwei (NCATS)
Tang, Hengli (Florida State University Research Foundation, Inc (FSURF))
Lee, Emily (Florida State University Research Foundation, Inc (FSURF))
YiChen, Cheng (Florida State University Research Foundation, Inc (FSURF))
Zhou, Yi (Florida State University Research Foundation, Inc (FSURF))
Song, Hongjun (Johns Hopkins University)
Ming, Guo-Li (Johns Hopkins University)
Wen, Zhexing (Johns Hopkins University)
Applications
Therapeutics
Research Materials
Therapeutic Areas
Neurology
Infectious Disease
Lead IC
NCATS
ICs
NCATS
This invention includes the discovery and use of a group of CDK inhibitors that were found during a drug repurposing screen designed to find compounds that inhibit Zika virus caused cell death. The identified CDK inhibitors have all previously been used in clinical trials for other diseases, potentially reducing the long time course needed for new drug discovery and development.
Commercial Applications
The group of identified CDK inhibitors could be used with an animal model to test for in vivo efficacy and to optimize the chemistry of the lead compounds.
Competitive Advantages
Repurposing CDK inhibitors that have been used in clinical trials for other diseases for the treatment of Zika virus infection can reduce the long time course needed for new drug discovery and development.
Licensing Contact: